DekaBank Deutsche Girozentrale’s Kymera Therapeutics KYMR Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio KYMR Stock Details KYMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-23,562	Closed	-$878K	–	1249
2025 Q4	$878K	Hold	23,562	–	–	﹤0.01%	903
2025 Q3	$869K	Hold	23,562	–	–	﹤0.01%	898
2025 Q2	$876K	Hold	23,562	–	–	﹤0.01%	891
2025 Q1	$951K	Hold	23,562	–	–	﹤0.01%	861
2024 Q4	$766K	Hold	23,562	–	–	﹤0.01%	925
2024 Q3	$801K	Hold	23,562	–	–	﹤0.01%	927
2024 Q2	$714K	Hold	23,562	–	–	﹤0.01%	943
2024 Q1	$950K	Buy	23,562 +1,562	+7%	+$55.9K	﹤0.01%	887
2023 Q4	$590K	Hold	22,000	–	–	﹤0.01%	1003
2023 Q3	$315K	Hold	22,000	–	–	﹤0.01%	1119
2023 Q2	$493K	Hold	22,000	–	–	﹤0.01%	1030
2023 Q1	$622K	Hold	22,000	–	–	﹤0.01%	972
2022 Q4	$564K	Hold	22,000	–	–	﹤0.01%	1009
2022 Q3	$491K	Hold	22,000	–	–	﹤0.01%	1045
2022 Q2	$446K	Hold	22,000	–	–	﹤0.01%	1036
2022 Q1	$913K	Buy	22,000 +2,000	+10%	+$84.5K	﹤0.01%	926
2021 Q4	$1.26M	Buy	+20,000	New	+$1.16M	﹤0.01%	887

Other funds holding KYMR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

DekaBank Deutsche Girozentrale's KYMR Position: Q1 2026 in Review

DekaBank Deutsche Girozentrale sold out of Kymera Therapeutics (KYMR) in Q1 2026, closing a stake of 23,562 shares — an estimated $878K sold.

DekaBank Deutsche Girozentrale first reported a position in KYMR in Q4 2021 and held it in 17 quarters. The position peaked at $1.26M in Q4 2021. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

DekaBank Deutsche Girozentrale reported no remaining Kymera Therapeutics position as of Q1 2026 after selling out during the quarter.
DekaBank Deutsche Girozentrale sold 23,562 Kymera Therapeutics shares in Q1 2026, an estimated $878K.
DekaBank Deutsche Girozentrale first reported a position in Kymera Therapeutics in Q4 2021 and held it in 17 quarters.
DekaBank Deutsche Girozentrale's Kymera Therapeutics position peaked at $1.26M in Q4 2021.
256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q1 2026, filed 7 May 2026.